Wells A. Messersmith

Medicine, University of Colorado Denver Anschutz Medical Campus

Affiliated withUniversity of Colorado Denver Anschutz Medical Campus

Research Area

Biography

Wells A. Messersmith has not added Biography.
If you are Wells A. Messersmith and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 23	2016

Other Publications

Article	Year
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15475439	2004
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for ... Journal of chromatography. B, Analytical technologies in the biomedical and life sciences\| PubMed ID: 16253576	2005
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16322314	2005
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16489083	2006
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacol... Journal of pharmaceutical and biomedical analysis\| PubMed ID: 16765012	2006
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences\| PubMed ID: 16798122	2007
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Annals of surgical oncology\| PubMed ID: 16955384	2006
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 17084620	2007
Novel targets in solid tumors: MEK inhibitors. Clinical advances in hematology & oncology : H&O\| PubMed ID: 17143253	2006
Assessment of celecoxib pharmacodynamics in pancreatic cancer. Molecular cancer therapeutics\| PubMed ID: 17172427	2006
Myeloid growth factors. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 17335688	2007
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 17429623	2008
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17699842	2007
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 18379785	2008
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer research\| PubMed ID: 18413752	2008
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18421048	2008
No time to waste: decreasing patient wait times for chemotherapy administration using automated prioritization in an oncology pharmacy system. The American journal of managed care\| PubMed ID: 18488295	2008
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18757332	2008
Targeting EGFR in colorectal cancer. The New England journal of medicine\| PubMed ID: 18946069	2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18955447	2008
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 19124802	2009
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 19380450	2009
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer journal (Sudbury, Mass.)\| PubMed ID: 19390304	2009
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19509160	2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Molecular cancer therapeutics\| PubMed ID: 19509264	2009
KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. The Journal of molecular diagnostics : JMD\| PubMed ID: 20007845	2010
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Investigational new drugs\| PubMed ID: 20084425	2011
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Investigational new drugs\| PubMed ID: 20306339	2011
Novel agents in the treatment of metastatic colorectal cancer. Cancer journal (Sudbury, Mass.)\| PubMed ID: 20526106	2010
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitog... Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20554751	2010
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20682712	2010
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Molecular cancer therapeutics\| PubMed ID: 20923857	2010
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 21051221	2011
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Translational oncology\| PubMed ID: 21151476	2010
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clinical colorectal cancer\| PubMed ID: 21208844	2010
Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park, N.Y.)\| PubMed ID: 21294478	2010
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22179664	2012
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22338014	2012
Patient-derived tumour xenografts as models for oncology drug development. Nature reviews. Clinical oncology\| PubMed ID: 22508028	2012
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer. Molecular oncology\| PubMed ID: 22521243	2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 22529266	2012
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22553375	2012
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Investigational new drugs\| PubMed ID: 22615057	2013
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22693357	2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet. Oncology\| PubMed ID: 22805291	2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. The Lancet. Oncology\| PubMed ID: 22805292	2012
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia (New York, N.Y.)\| PubMed ID: 22952422	2012
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer\| PubMed ID: 23132335	2013
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer medicine\| PubMed ID: 23342270	2012
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in pharmacology\| PubMed ID: 23543898	2013
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Molecular oncology\| PubMed ID: 23607916	2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23757356	2013
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clinical colorectal cancer\| PubMed ID: 24075777	2013
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24493827	2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 24633809	2014
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25231399	2015
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. International journal of cancer\| PubMed ID: 25242168	2015
An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIα and potent anticancer agent. Marine drugs\| PubMed ID: 25244109	2014
A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25388167	2015
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PloS one\| PubMed ID: 25401499	2014
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25724527	2015
Right to try? Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 25779561	2015
Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 26085388	2015
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in pharmacology\| PubMed ID: 26136684	2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. International journal of cancer\| PubMed ID: 26152787	2016
Targeting the WNT Signaling Pathway in Cancer Therapeutics. The oncologist\| PubMed ID: 26306903	2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 26392102	2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget\| PubMed ID: 26439693	2015
Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma. Pancreas\| PubMed ID: 26566217	2016
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. Journal of clinical pharmacology\| PubMed ID: 26632033	2016
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Investigational new drugs\| PubMed ID: 26715573	2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget\| PubMed ID: 27070088	2016
Therapeutic Approaches to RAS Mutation. Cancer journal (Sudbury, Mass.)\| PubMed ID: 27341593	2016
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget\| PubMed ID: 27385211	2016
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. Journal of the National Cancer Institute\| PubMed ID: 27634934	2017